A Prospective Study Looking at the Use of Rebif® in Subjects With Clinically Isolated Syndrome
Status:
Completed
Trial end date:
2008-11-01
Target enrollment:
Participant gender:
Summary
The primary objective of this initiative is to assess the effectiveness of subcutaneous (sc)
interferon (IFN) beta - 1a, (Rebif®), versus No Treatment in delaying the conversion to
Clinically Definite Multiple Sclerosis (CDMS) - as defined by the occurrence of a second
exacerbation - over 96 weeks in subjects that present with Clinically Isolated Syndrome (CIS)
accompanied by an abnormal magnetic resonance imaging (MRI). The secondary objectives are to:
- Assess the effectiveness of sc IFN beta - 1a (Rebif®) therapy in reducing the proportion
of patients with CIS converting to CDMS
- Assess the safety of sc IFN beta - 1a (Rebif®) in the patients with CIS